Page 6,677«..1020..6,6766,6776,6786,679..6,6906,700..»

Allen defends C4 Drugs Live show

Posted: Published on July 16th, 2012

16 July 2012 Last updated at 09:36 ET Keith Allen has defended a forthcoming Channel 4 series in which he is filmed taking drugs. The musician and actor took MDMA, the pure form of ecstasy, for the upcoming documentary to examine its effects. Health campaigners said the show ran the risk of being "voyeuristic" and "unrepresentative". But the 59-year-old actor and musician said the documentary was designed as a "forensic analysis" into the physical and psychological effects of drugs. Called Drugs Live, the "radical" four-part series aims to examine the claims and counterclaims made about recreational drugs by testing them in a monitored environment. TV bosses at Channel 4 said the series, to be broadcast in the autumn, would "provide viewers with unmediated access to a live drug trial". Speaking on ITV 1's This Morning, Allen said it was "insane" to suggest the show glamorised drug use. "If you think that I'm glamorising the taking of drugs by spending an hour and 20 minutes for two consecutive Mondays in an MRI scanning machine, then you're insane. We wouldn't want anyone to come away from the programme thinking that MDMA is benign. Read more here: Allen defends C4 Drugs Live show … Continue reading →

Posted in Drugs | Comments Off on Allen defends C4 Drugs Live show

(Metro News) UMAK opens center of Pharmacy

Posted: Published on July 16th, 2012

MANILA The city government-owned University of Makati has opened its Center of Pharmacy, the first of its kind in the country, under the College of Allied Health Studies (COAHS) for this school year 2012-2013. In a report to Makati Mayor Jejomar Erwin S. Binay, university president Tomas Lopez said the Center of Pharmacy offers a six-year ladderized program consisting of the following two-year courses: Associate of Applied Science in Pharmaceutical Technology; Bachelor of Science in Pharmacy with added specialization in Pharmaceutical Marketing, and Doctor of Pharmacy. Lopez said under the program, graduates of the first two-year course, Associate of Applied Science in Pharmaceutical Technology, could already work competently as skilled pharmacy technicians and pharmacy assistants under the supervision of a licensed pharmacist in settings such as a community pharmacy, hospital pharmacy or a healthcare institution. He or she may also work independently as research assistant, and also in pharmaceutical, cosmetic or medical equipment dealerships. Graduates of the said course have the option to pursue a degree in Bachelor of Science in Pharmacy, which offers added specialization in Pharmaceutical Marketing. Those who want to be a licensed pharmacist can continue for two more years to complete the professional program. UMAK is … Continue reading →

Posted in Pharmacy | Comments Off on (Metro News) UMAK opens center of Pharmacy

UCB Launches Neupro® in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome

Posted: Published on July 16th, 2012

BRUSSELS & ATLANTA--(BUSINESS WIRE)-- UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S. Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinsons disease and moderate-to-severe primary Restless Legs Syndrome. Neupro improves motor function and activities of daily living in patients with PD and provides effective symptom relief for patients with Restless Legs Syndrome (RLS). Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours. Over 100,000 patients have been treated with Neupro worldwide, and seven clinical trials for the approved indications have demonstrated efficacy, safety and tolerability. The availability of Neupro is an important step forward for U.S. patients living with Parkinsons disease and Restless Legs Syndrome, said Roch Doliveux, Chief Executive Officer, UCB. "UCB is dedicated to delivering innovative medicines like the Neupro transdermal patch to people living with serious illnesses such as Parkinsons disease and Restless Legs Syndrome, by combining the latest science and technology with our researchers' insights on the holistic needs of patients. One million Americans are currently living with PD. The cardinal motor symptoms of PD include … Continue reading →

Posted in Parkinson's Treatment | Comments Off on UCB Launches Neupro® in the U.S. to Treat Parkinson’s Disease and Restless Legs Syndrome

Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson …

Posted: Published on July 16th, 2012

PLAN-LES-OUATES GENEVA, SWITZERLAND--(Marketwire -07/16/12)- Addex Therapeutics / Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Modulation on Motor Symptoms in Parkinson's disease Geneva, Switzerland, 16 July 2012 - Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based oral small molecule drug discovery and development, announced today the publication of positive pre- clinical efficacy data on its novel, highly selective oral small molecule positive allosteric modulator (PAM) of metabotropic glutamate receptor 4 (mGluR4), and its role in Parkinson's disease. The results were published in the Journal of Pharmacology and Experimental Therapeutics (JPET) on 11 July 2012 as DOI:10.1124/jpet.112.196063. The researchers report the discovery of ADX88178, a novel, potent, brain penetrant and selective mGluR4 PAM, with drug- like properties, to explore the therapeutic potential of mGluR4 modulation in disease models. The research was conducted in collaboration with Merck & Co. "There continues to be a significant need for new approaches to treat Parkinson's disease. Research shows that increasing mGluR4 activity … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson …

Taxpayers sweat the cost of 'healing' trip

Posted: Published on July 16th, 2012

A supplied picture of a modern Cree sweat lodge. Source: Supplied TAXPAYERS will fork out almost $21,000 to send a north Queensland assault victim overseas for spiritual healing on an Indian reserve. "Indigenous Canadian" Ruth Schaefer will fly with her friend, Hope Vale Aboriginal elder Gordon Charlie, on the trip to Cree Nations Treatment Haven in Saskatchewan, Canada - with both airfares paid for by the Justice Department. A Queensland tribunal ordered the trip, finding it "reasonable", as the treatment was only available in Canada. It found Ms Schaefer needed an escort and at least two stopovers each way. Ms Schaefer, who has post-traumatic stress disorder after a violent assault in 2007, went to Cree Nations in 2005 for trauma treatment in a sweat lodge and "a linking back to spiritual ancestors". The Canadian woman, who lives in Mareeba in north Queensland, said she now needs to return to the centre for "spiritual healing". At a Queensland Civil and Administrative hearing last month, Mr Charlie, who has known Ms Schaefer for 20 years, told QCAT that the healing programs for indigenous people in Australia were ineffective. The Justice Department previously rejected Ms Schaefer's request for financial assistance for the trip, … Continue reading →

Posted in MS Treatment | Comments Off on Taxpayers sweat the cost of 'healing' trip

Research improving lives for MS patients

Posted: Published on July 16th, 2012

Discovering new medicines is often the first thing that comes to mind when people think about clinical trials. But some of the most important research occurs in optimizing previously approved drugs. These follow-up studies are used to test the tolerability of drugs already approved, optimize patient safety and address patient acceptance. An example of this type of research is underway now at The Corvallis Clinic involving patients who have multiple sclerosis. MS is a disease affecting the central nervous system, brain and spinal cord, causing problems with muscle control and strength, vision, balance, feeling and thinking. The Clinics Research Center participated in a previous study to evaluate fingolimod, marketed as Gilenya, the first-ever pill for treating the most common form of the disease, relapsing remitting MS. With relapsing remitting MS, patients experience attacks or relapses of symptoms, which are followed by periods of partial or complete recovery. Prior to Gilenya, medication was only available by injection. Although most patients are able to give themselves shots at home, it was a pain and a literal discomfort. These shots were also leading to a compliance problem, with patients not wanting to take their medicine. In studies, patients taking Gilenya showed improved compliance. … Continue reading →

Posted in MS Treatment | Comments Off on Research improving lives for MS patients

UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis

Posted: Published on July 16th, 2012

Public release date: 15-Jul-2012 [ | E-mail | Share ] Contact: Jim Fessenden james.fessenden@umassmed.edu 508-856-2000 University of Massachusetts Medical School WORCESTER, Mass. A new genetic mutation that causes familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease, has been identified by a team of scientists led by researchers at the University of Massachusetts Medical School (UMMS). Mutations to the profilin (PFN1) gene, which is essential to the growth and development of nerve cell axons, is estimated to account for one to two percent of inherited ALS cases. The finding, described today in the online edition of Nature, points to defects in a neuron's cytoskeleton structure as a potential common feature among diverse ALS genes. "This discovery identifies what may possibly be a common biological mechanism involved across familial ALS cases regardless of genetics," said John Landers, PhD, associate professor of neurology and senior author of the study. "We know of at least three other ALS genes, in addition to PFN1, that adversely impact axon growth. If indeed, this is part of the disease's mechanism, then it might also be a potential target for therapeutics." Robert Brown, MD, DPhil, a co-author on the study and … Continue reading →

Comments Off on UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis

USF institute might reform patient diagnosis

Posted: Published on July 16th, 2012

By LINDSAY PETERSON | The Tampa Tribune Published: July 16, 2012 Updated: July 16, 2012 - 6:00 AM Stephen Liggett isn't crazy about the term personalized medicine, though he's been practicing it for nearly two decades as a doctor and scientist. Good doctors have personalized their treatment for centuries, he said. But this is different. Game-change different. The University of South Florida has created a Personalized Medicine Institute and hired Liggett from the University of Maryland to put it together and elevate it to national prominence. He's in charge of ushering in a fundamentally new kind of health care to Florida. It's based on this idea: Key information about a person's health and response to drug treatment is locked inside his genetic code, and that information should guide every doctor's treatment decisions. It's the antithesis to the "one-size-fits-all" approach that dominates health care treatment across the country, Liggett said. For instance, if you have heart trouble, your doctor will probably prescribe Coumadin, a drug that prevents blood from clotting and precipitating a heart attack or stroke. Millions of people take it. But if you have a certain genetic makeup, Coumadin could cause fatal side effects. Follow this link: USF institute … Continue reading →

Comments Off on USF institute might reform patient diagnosis

Propecia Linked to Long-Term Sexual Dysfunction in Some Men

Posted: Published on July 15th, 2012

Attorney (866) 735-1102 Ext 430 About a month ago reports emerged that Propecia, the drug to treat male pattern baldness, was linked to sexual side effects in men including low libido, ejaculation disorders, and orgasm disorders. Those findings led the FDA to demand that Merck, the maker of Propecia, change the drug's warning label to reflect these dangerous side effects. However, more recent reports suggest that the side effects may be even more drastic than originally thought. The sexual side effects may be longer lasting in some men who take Propecia, although it was originally believed that these side effects would disappear once a person stopped taking the drug. However, researchers at George Washington University found that the effects could last longer than a year after stopping the drug. In fact, after talking to 54 men under the age of 40 who had taken Propecia and stopped use, 96% reported sexual side effects a year after the fact. One man, Kevin Malley, started to take Propecia when he was under the age of 30 to stave off impending baldness. His doctor prescribed Propecia and Malley started taking it in May 2011. By October, Malley was completely impotent, had no sex … Continue reading →

Posted in Drug Side Effects | Comments Off on Propecia Linked to Long-Term Sexual Dysfunction in Some Men

People's Pharmacy: Relief for bra itch

Posted: Published on July 15th, 2012

Q: I have been suffering with a rash under my breasts. Every morning, I use antiperspirant under my breasts. Although it does seem to help, the itching and discomfort have never gone away. Underwire bras are iffy, and lace is out of the question. I itch like crazy, and I have red marks, so at the end of the day I can't wait to get my bra off. What can you recommend? A: We don't know what is causing your itchy rash, but many women develop a fungal infection in those warm, moist areas under the breasts. Keeping the area dry can be crucial. Although an antiperspirant may reduce sweating, another reader has a different suggestion: "I had bra itch for months and was unsuccessful in treating it until I tried Zeasorb-AF. I can't believe the difference. In just over a week, it has dried up the rash and stopped the itching. It takes some getting used to the medicinal aroma. They market it for athlete's foot, and it has an antifungal drug called miconazole in it. It's worth a try!" We hope the Zeasorb-AF will help you, too. Another approach that may be worthwhile would be a spray-on athlete's … Continue reading →

Posted in Pharmacy | Comments Off on People's Pharmacy: Relief for bra itch

Page 6,677«..1020..6,6766,6776,6786,679..6,6906,700..»